Prophylaxis of migraine headaches with riboflavin: A systematic review
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2017/05/08
-
Indian UGC (journal)
-
Refrences56
-
Citations62
-
D. F. Thompson Pharmaceutical Sciences; College of Pharmacy; Southwestern Oklahoma State University; Weatherford OK USA
-
H. S. Saluja Pharmaceutical Sciences; College of Pharmacy; Southwestern Oklahoma State University; Weatherford OK USA
Cite
Thompson, D. F., and H. S. Saluja. “Prophylaxis of Migraine Headaches With Riboflavin: A Systematic Review”. Journal of Clinical Pharmacy and Therapeutics, vol. 42, no. 4, 2017, pp. 394-03, https://doi.org/10.1111/jcpt.12548.
Thompson, D. F., & Saluja, H. S. (2017). Prophylaxis of migraine headaches with riboflavin: A systematic review. Journal of Clinical Pharmacy and Therapeutics, 42(4), 394-403. https://doi.org/10.1111/jcpt.12548
Thompson DF, Saluja HS. Prophylaxis of migraine headaches with riboflavin: A systematic review. Journal of Clinical Pharmacy and Therapeutics. 2017;42(4):394-403.
Journal Categories
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
You May Also Like
- A Bayesian neural network method for adverse drug reaction signal generation
- Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
- Clinical consequences of polypharmacy in elderly
- Long-term side effects of glucocorticoids
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond | Neurological Sciences |
| 63 | 2010 |
| Development and testing of the Migraine Disability Assessment (MIDAS) questionnaire to assess headache-related disability | Neurology |
| 2001 | |
| The burden of neurological disease in the United States: A summary report and call to action | Annals of Neurology |
| 230 | 2017 |
General lack of use of placebo in prophylactic, randomised, controlled trials in adult migraine. A systematic review | Cephalalgia |
| 8 | 2016 |
| What Constitutes an “Adequate” Trial in Migraine Prevention? | Current Pain and Headache Reports |
| 1 | 2015 |
Refrences Analysis
The category
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry 23
is the most frequently represented among the references in this article. It primarily includes studies from Neurology The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Headache Management in Individuals with Brain Tumor | Seminars in Neurology |
| 2024 | |
| Zinc Administration Favorably Affects Prophylactic Therapy-refractory Migraine Attacks: A Case Series | Internal Medicine |
| 2024 | |
Migraine drugs | ChemTexts |
| 2023 | |
Defining metabolic migraine with a distinct subgroup of patients with suboptimal inflammatory and metabolic markers | Scientific Reports |
| 3 | 2023 |
| Migraine prevention: initial treatment options | BMJ |
| 1 | 2023 |
Citations Analysis
The category
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry 24
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Riboflavin Has Neuroprotective Potential: Focus on Parkinson’s Disease and Migraine and was published in 2017. The most recent citation comes from a 2024 study titled Headache Management in Individuals with Brain Tumor. This article reached its peak citation in 2022, with 14 citations. It has been cited in 49 different journals, 20% of which are open access. Among related journals, the Scientific Reports cited this research the most, with 4 citations. The chart below illustrates the annual citation trends for this article.